Clinical Trials Sponsored by Immune Design

Total 667 results

Immune-Onc Therapeutics
Regeneron Pharmaceuticals

Completed

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA)

Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for MLD

Metachromatic Leukodystrophy (MLD)

China
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific T Cells Against Lung Cancer

Lung Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of CAR-T Against Cervical Cancer

Cervical Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Unknown

Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders

Tissue Damage | Immune Related Disorder

China
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

Beta-Thalassemia

China
Tufts Medical Center
Immune Control

Terminated

Fluphenazine Decanoate for Psoriasis

Psoriasis

United States
Paragon 28
Focus Medical Design and Development

Completed

An Evaluation Of Healthy Ankle Motion And Morphology

Healthy Ankle

United States
Inmune Bio, Inc.

Recruiting

Study of INKmune in Patients With mCRPC (CaRe Prostate) (CaRe)

Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

United States
Inmune Bio, Inc.

Recruiting

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation (MINDFuL)

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies | Mild Cognitive Impairment

Australia, Canada, United Kingdom, Poland, Germany
Aimmune Therapeutics, Inc.

Completed

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Peanut Allergy

United States, Canada, Spain, Netherlands, Germany, United Kingdom, Ireland, Sweden, France, Italy
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
IMMUNOe Research Centers

Unknown

Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Covid19 | Post-Viral Fatigue Syndrome | Post-Viral Disorder (Disorder)

United States
Timmune Biotech Inc.

Unknown

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

Non-hodgkin Lymphoma,B Cell

China
Amgen
Immunex Corporation

Terminated

Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis
IMMUNOe Research Centers

Completed

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Primary Immunodeficiency
Bionor Immuno AS

Completed

Re-boosting of HIV-1 Infected Subjects With Vacc-4x (Re-boost)

HIV-1 Infection

United States, Spain, Germany, Italy, United Kingdom
Amgen
Immunex Corporation

Completed

Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials

Rheumatoid Arthritis
Amgen
Immunex Corporation

Completed

Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis
Amgen
Immunex Corporation

Completed

Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders

Rheumatoid Arthritis
Amgen
Immunex Corporation

Completed

Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis

Psoriasis | Psoriatic Arthritis
Shenzhen Geno-Immune Medical Institute

Recruiting

Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells

Autoimmune Diseases

China
Boston Immune Technologies and Therapeutics

Not yet recruiting

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Peripheral T-cell Lymphoma | NHL | Cutaneous T Cell Lymphoma
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

China
Immune Response BioPharma, Inc.
cro

Recruiting

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis | Secondary Progress Multiple Sclerosis

United States
Cargill
Natural Immune Systems Inc

Completed

EpiCor Clinical Study on Rapid Immune Modulating Effects

Immune Surveillance

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Genetically Modified T Cells Against Ovarian Cancer

Ovarian Cancer

China
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of Bladder Cancer by CAR-T

Bladder Cancer | Urothelial Carcinoma Bladder

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral Gene Therapy for X-ALD

X-linked Adrenoleukodystrophy

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Tuberculosis | CMV Infection | EBV Infection | Adenovirus Infection | Fungus Infection | Pathogen Infection | BKV Infection

China
Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FIX Gene Therapy

Hemophilia B
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FVIII Gene Therapy

Hemophilia A

China
Shenzhen Geno-Immune Medical Institute

Suspended

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Ovarian Cancer

China
Tufts Medical Center
Immune Control

Completed

Fluphenazine Hydrochloride for Psoriasis (FP-CL2)

Psoriasis

United States
Habit Design
University of Washington; TriHealth Inc.

Recruiting

Promoting Healthy Habits in Metabolic Syndrome

Metabolic Syndrome

United States
University of Florida
Villency Design Group, LLC

Completed

Villency-Proof of Action: Foot Device, Balance and Sway, Kinematics of Walking

Balance

United States
University of South Florida
Design Interactive, Inc

Unknown

Enhanced Auto-Diagnostic Adaptive Precision Trainer for Myoelectric Prosthetic Users (eADAPT)

Amputation

United States
Inmune Bio, Inc.

Active, not recruiting

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies

Australia
Inmune Bio, Inc.

Terminated

A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Cancer | AML | MDS-EB

United Kingdom, Greece
Inmune Bio, Inc.

Terminated

INB03 for the Treatment of Pulmonary Complications From COVID-19

COVID-19

United States

Clinical Trials Sponsored by Immune Design

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations